CA
ADMA icon

Continuum Advisory’s ADMA Biologics ADMA Stock Holding History

Continuum Advisory’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-230
Closed -$4.56K – 438
2025
Q1 		$4.56K Hold
230
– – ﹤0.01% 1127
2024
Q4 		$3.94K Sell
230
-35
-13% -$658 ﹤0.01% 1197
2024
Q3 		$5.35K Sell
265
-145
-35% -$2.25K ﹤0.01% 1137
2024
Q2 		$4.58K Hold
410
– – ﹤0.01% 1095
2024
Q1 		$2.84K Buy
+410
New +$2.24K ﹤0.01% 1201

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Continuum Advisory's ADMA Position: Q2 2025 in Review

Continuum Advisory sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 230 shares — an estimated $4.56K sold.

Continuum Advisory first reported a position in ADMA in Q1 2024 and held it in 5 quarters. The position peaked at $5.35K in Q3 2024. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Continuum Advisory reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 230 ADMA Biologics shares in Q2 2025, an estimated $4.56K.
  • Continuum Advisory first reported a position in ADMA Biologics in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's ADMA Biologics position peaked at $5.35K in Q3 2024.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.